Literature DB >> 20922345

Clinic visits and prescribing patterns among Veterans Affairs Maryland Health Care System dementia patients.

G B Rattinger1, C D Mullins, I H Zuckerman, E Onukwugha, S Delisle.   

Abstract

OBJECTIVE: Our objective was to determine how patient demographics and outpatient referrals to specialized dementia (DEM) or mental health (MH) clinics influence receipt of anti-dementia (AD), antidepressant (ADEP), antipsychotic (APSY) and sedative-hypnotic (SEDH) medications among veterans with dementia.
DESIGN: Retrospective, cross-sectional observational study.
SETTING: Veterans Affairs Maryland Health Care System (VAMHCS). PARTICIPANTS: Veterans aged ≥ 60 years with Alzheimer's or related dementia diagnosis after 1999 with minimum of one-year follow-up or death were included. MEASUREMENTS: Retrospective analysis of VAMHCS electronic medical records were used to determine predictors of AD, ADEP, APSY, and SEDH prescribing using logistic regression models that examined visits to DEM or MH clinics, patient age, follow-up time, race/ethnicity and marital status.
RESULTS: Among 1209 veterans with average follow-up of 3.2 (SD 1.9) years, 36% percent had MH visits, 38% had DEM visits and 19% visited both clinics. DEM visits were associated with AD and ADEP but not APSY medication receipt (OR(AD:DEM) = 1.47, 95% CI = (1.052, 2.051); OR(ADEP:DEM) = 1.66, 95% CI = (1.193, 2.302); OR(APSY:DEM) = 1.35, 95% CI = (0.941, 1.929)). MH visit was associated with ADEP and APSY medication receipt (OR(AD:MH)\ = 1.16, 95% CI = (0.821, 1.631); OR(ADEP:MH) = 2.83, 95% CI = (2.005, 4.005); OR (APSY:MH) = 4.41, 95% CI = (3.109, 6.255)).
CONCLUSION: In the VAMHCS dementia population, visits to DEM or MH specialty clinics increase the odds of receiving AD, ADEP, and APSY medications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20922345     DOI: 10.1007/s12603-010-0315-3

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  40 in total

1.  Depression as a risk factor for later dementia: a robust relationship?

Authors:  Alex J Mitchell
Journal:  Age Ageing       Date:  2005-05       Impact factor: 10.668

Review 2.  Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.

Authors:  D P Rice; H M Fillit; W Max; D S Knopman; J R Lloyd; S Duttagupta
Journal:  Am J Manag Care       Date:  2001-08       Impact factor: 2.229

3.  Depressive syndromes and functional disability in dementia.

Authors:  R Hargrave; B Reed; D Mungas
Journal:  J Geriatr Psychiatry Neurol       Date:  2000       Impact factor: 2.680

4.  Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  D S Knopman; S T DeKosky; J L Cummings; H Chui; J Corey-Bloom; N Relkin; G W Small; B Miller; J C Stevens
Journal:  Neurology       Date:  2001-05-08       Impact factor: 9.910

5.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

6.  Racial and ethnic disparities in the treatment of dementia among Medicare beneficiaries.

Authors:  Ilene H Zuckerman; Priscilla T Ryder; Linda Simoni-Wastila; Thomas Shaffer; Masayo Sato; Lirong Zhao; Bruce Stuart
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2008-09       Impact factor: 4.077

Review 7.  Neurocognitive impairment and dementia in mood disorders.

Authors:  Andrea Pfennig; Eckhard Littmann; Michael Bauer
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2007       Impact factor: 2.198

8.  Burden of Alzheimer's disease and association with negative health outcomes.

Authors:  Daniel C Malone; Trent P McLaughlin; Peter M Wahl; Christopher Leibman; H Michael Arrighi; Mark J Cziraky; Lisa M Mucha
Journal:  Am J Manag Care       Date:  2009-08       Impact factor: 2.229

9.  Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE.

Authors:  Lars Bertram; Christoph Lange; Kristina Mullin; Michele Parkinson; Monica Hsiao; Meghan F Hogan; Brit M M Schjeide; Basavaraj Hooli; Jason Divito; Iuliana Ionita; Hongyu Jiang; Nan Laird; Thomas Moscarillo; Kari L Ohlsen; Kathryn Elliott; Xin Wang; Diane Hu-Lince; Marie Ryder; Amy Murphy; Steven L Wagner; Deborah Blacker; K David Becker; Rudolph E Tanzi
Journal:  Am J Hum Genet       Date:  2008-10-30       Impact factor: 11.025

Review 10.  Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

Authors:  Parminder Raina; Pasqualina Santaguida; Afisi Ismaila; Christopher Patterson; David Cowan; Mitchell Levine; Lynda Booker; Mark Oremus
Journal:  Ann Intern Med       Date:  2008-03-04       Impact factor: 25.391

View more
  5 in total

1.  Health economics and health policy issues in Alzheimer's disease.

Authors:  T Rapp
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 2.  Advancing Alzheimer's research: A review of big data promises.

Authors:  Rui Zhang; Gyorgy Simon; Fang Yu
Journal:  Int J Med Inform       Date:  2017-07-24       Impact factor: 4.046

3.  Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Authors:  Ganesh M Babulal; Yakeel T Quiroz; Benedict C Albensi; Eider Arenaza-Urquijo; Arlene J Astell; Claudio Babiloni; Alex Bahar-Fuchs; Joanne Bell; Gene L Bowman; Adam M Brickman; Gaël Chételat; Carrie Ciro; Ann D Cohen; Peggye Dilworth-Anderson; Hiroko H Dodge; Simone Dreux; Steven Edland; Anna Esbensen; Lisbeth Evered; Michael Ewers; Keith N Fargo; Juan Fortea; Hector Gonzalez; Deborah R Gustafson; Elizabeth Head; James A Hendrix; Scott M Hofer; Leigh A Johnson; Roos Jutten; Kerry Kilborn; Krista L Lanctôt; Jennifer J Manly; Ralph N Martins; Michelle M Mielke; Martha Clare Morris; Melissa E Murray; Esther S Oh; Mario A Parra; Robert A Rissman; Catherine M Roe; Octavio A Santos; Nikolaos Scarmeas; Lon S Schneider; Nicole Schupf; Sietske Sikkes; Heather M Snyder; Hamid R Sohrabi; Yaakov Stern; Andre Strydom; Yi Tang; Graciela Muniz Terrera; Charlotte Teunissen; Debora Melo van Lent; Michael Weinborn; Linda Wesselman; Donna M Wilcock; Henrik Zetterberg; Sid E O'Bryant
Journal:  Alzheimers Dement       Date:  2018-12-13       Impact factor: 21.566

4.  Racial/ethnic disparities in initiation and persistent use of anti-dementia medications.

Authors:  Carolyn W Zhu; Judith Neugroschl; Lisa L Barnes; Mary Sano
Journal:  Alzheimers Dement       Date:  2022-02-25       Impact factor: 16.655

5.  Changes in the use of psychotropic drugs during the course of Alzheimer's disease: A large-scale longitudinal study of French medical records.

Authors:  Manon Ansart; Stéphane Epelbaum; Marion Houot; Thomas Nedelec; Béranger Lekens; Laurène Gantzer; Didier Dormont; Stanley Durrleman
Journal:  Alzheimers Dement (N Y)       Date:  2021-09-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.